Free Trial
NASDAQ:UPB

Upstream Bio (UPB) Stock Price, News & Analysis

Upstream Bio logo
$8.70 -0.66 (-7.04%)
As of 09:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Upstream Bio Stock (NASDAQ:UPB)

Advanced

Key Stats

Today's Range
$8.51
$9.52
50-Day Range
$7.66
$10.49
52-Week Range
$7.25
$33.68
Volume
568,770 shs
Average Volume
519,213 shs
Market Capitalization
$473.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.75
Consensus Rating
Hold

Company Overview

Upstream Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

UPB MarketRank™: 

Upstream Bio scored higher than 37% of companies evaluated by MarketBeat, and ranked 576th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Upstream Bio has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Upstream Bio has a consensus price target of $38.75, representing about 340.8% upside from its current price of $8.79.

  • Amount of Analyst Coverage

    Upstream Bio has only been the subject of 3 research reports in the past 90 days.

  • Read more about Upstream Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Upstream Bio are expected to decrease in the coming year, from ($3.06) to ($3.21) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Upstream Bio is -3.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Upstream Bio is -3.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Upstream Bio has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.85% of the float of Upstream Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Upstream Bio has a short interest ratio ("days to cover") of 5.71.
  • Change versus previous month

    Short interest in Upstream Bio has recently increased by 6.64%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Upstream Bio does not currently pay a dividend.

  • Dividend Growth

    Upstream Bio does not have a long track record of dividend growth.

  • News Sentiment

    Upstream Bio has a news sentiment score of -0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Upstream Bio this week, compared to 3 articles on an average week.
  • Search Interest

    2 people have searched for UPB on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Upstream Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,915.00 in company stock.

  • Percentage Held by Insiders

    13.56% of the stock of Upstream Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Upstream Bio has minimal institutional ownership at this time.

  • Read more about Upstream Bio's insider trading history.
Receive UPB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Upstream Bio and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

UPB Stock News Headlines

Upstream Bio (NASDAQ:UPB) Price Target Lowered to $50.00 at Mizuho
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…tc pixel
See More Headlines

UPB Stock Analysis - Frequently Asked Questions

Upstream Bio's stock was trading at $27.15 on January 1st, 2026. Since then, UPB stock has decreased by 67.6% and is now trading at $8.79.

Upstream Bio, Inc. (NASDAQ:UPB) posted its earnings results on Wednesday, May, 13th. The company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.73) by $0.02. The business had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.03 million. Upstream Bio had a negative net margin of 4,718.96% and a negative trailing twelve-month return on equity of 41.73%.

Upstream Bio (UPB) raised $200 million in an IPO on Friday, October 11th 2024. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair served as the underwriters for the IPO.

Upstream Bio's top institutional shareholders include Decheng Capital LLC (5.01%), Y Intercept Hong Kong Ltd (1.84%), SEB Asset Management AB (1.61%) and Pictet Asset Management Holding SA (1.35%). Insiders that own company stock include Erez Chimovits, Ai Upstream Llc and Michael Gray.
View institutional ownership trends
.

Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/13/2026
Today
5/15/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:UPB
Previous Symbol
NASDAQ:UPB
CIK
2022626
Fax
N/A
Employees
38
Year Founded
2021

Price Target and Rating

High Price Target
$50.00
Low Price Target
$15.00
Potential Upside/Downside
+345.4%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.67)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$143.44 million
Net Margins
-4,718.96%
Pretax Margin
-5,026.03%
Return on Equity
-41.73%
Return on Assets
-40.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
26.15
Quick Ratio
26.15

Sales & Book Value

Annual Sales
$2.85 million
Price / Sales
166.14
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.29 per share
Price / Book
1.38

Miscellaneous

Outstanding Shares
54,420,000
Free Float
47,041,000
Market Cap
$473.51 million
Optionable
N/A
Beta
1.28

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:UPB) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners